Viva Biotech Holdings Leads The Charge In Asian Penny Stocks

9 hours ago 11

editorial-team@simplywallst.com (Simply Wall St)

Tue, May 13, 2025, 4:02 PM 4 min read

As planetary markets navigate a scenery marked by commercialized negotiations and economical uncertainty, Asia's fiscal country remains a focal constituent for investors seeking opportunities amid evolving conditions. Penny stocks, though an older term, inactive seizure the essence of investing successful smaller oregon emerging companies that tin connection important value. By focusing connected those with beardown financials and imaginable maturation paths, investors whitethorn uncover hidden gems wrong this conception of the market.

Name	Share Price	Market Cap	Financial Health Rating
Advice IT Infinite (SET:ADVICE)	THB4.90	THB3.04B	★★★★★★
T.A.C. Consumer (SET:TACC)	THB4.58	THB2.75B	★★★★★★
Tirathai (SET:TRT)	THB3.18	THB979.47M	★★★★★☆
CNMC Goldmine Holdings (Catalist:5TP)	SGD0.41	SGD166.17M	★★★★★☆
Beng Kuang Marine (SGX:BEZ)	SGD0.186	SGD37.05M	★★★★★★
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD2.21	SGD8.7B	★★★★★☆
Bosideng International Holdings (SEHK:3998)	HK$4.12	HK$47.17B	★★★★★★
Lever Style (SEHK:1346)	HK$1.17	HK$738.21M	★★★★★★
Goodbaby International Holdings (SEHK:1086)	HK$1.38	HK$2.3B	★★★★★★
TK Group (Holdings) (SEHK:2283)	HK$2.18	HK$1.82B	★★★★★★

Click present to spot the afloat database of 1,174 stocks from our Asian Penny Stocks screener.

Let's reappraisal immoderate notable picks from our screened stocks.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Viva Biotech Holdings is an concern holding institution that provides structure-based cause find services to biotechnology and pharmaceutical customers globally, with a marketplace headdress of HK$3.37 billion.

Operations: The company's gross is chiefly derived from its Drug Discovery Services, which generated CN¥821.31 million, and its Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥1.18 billion.

Market Cap: HK$3.37B

Viva Biotech Holdings has shown a important turnaround, reporting a nett income of CN¥167.29 cardinal for 2024, compared to a nonaccomplishment the erstwhile year. The company's gross streams are chiefly from Drug Discovery Services and CDMO services, totaling CN¥1.99 billion. Despite precocious stock terms volatility and an accrued debt-to-equity ratio implicit 5 years, its indebtedness is good covered by operating currency travel and involvement payments are adequately managed with EBIT sum of 6.9 times. Recent committee changes purpose to heighten governance amid improving operational ratio and concern gains contributing to profitability recovery.